Des Moines brewery named best brewpub in US for second year in a row

Des Moines' Lua Brewing has once again claimed the top spot as the No.1 brewpub in the country in the USA TODAY 10BEST ...
MassDevice

Novocure has reimbursement win for Optune Lua in Japan

Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its ...
Business Wire

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Cure Today

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...
The American Journal of Managed Care

FDA Approves Optune Lua Device in NSCLC

Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...
Des Moines Register

This Des Moines microbrewery was just named the best brewpub in the United States

The public has spoken: A Des Moines microbrewery was voted as the No. 1 brewpub in the country in the USA TODAY 10BEST Readers' Choice Awards. It beat out pubs from all over the country including ...
Hosted on MSN

Novocure announces Japan MHLW approval for Optune Lua

Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable ...